A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Fáze 1b/2 otevřená, multicentrická studie pro vyhodnocení bezpečnosti a účinnosti raludotatug deruxtecan s nebo bez jiných protinádorových vyšetřovacích látek u účastníků s vysoce kvalitním epiteliálním vaječníkem, primární peritoneální nebo vejdoucí rakovinou trubice, kteří se po předchozí platinové chemoterapii zacházeli
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.
Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:
- Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
- Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread
Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Toll Free Number
- Telefonní číslo: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studijní místa
-
-
Victoria
-
St Albans, Victoria, Austrálie, 3021
- Nábor
- Western Health-Sunshine & Footscray Hospitals ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +61402775432
-
-
-
-
-
Haifa, Izrael, 3109601
- Nábor
- Rambam Health Care Campus ( Site 0202)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 972-4-7776234
-
Jerusalem, Izrael, 9103102
- Nábor
- Shaare Zedek Medical Center ( Site 0201)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +972-(0)2-6555424
-
Petah Tikva, Izrael, 4941492
- Nábor
- Rabin Medical Center ( Site 0203)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +97239378076
-
Ramat Gan, Izrael, 5265601
- Nábor
- Sheba Medical Center ( Site 0200)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 972-3-5304498
-
-
-
-
-
Seoul, Jižní Korea, 03080
- Nábor
- Seoul National University Hospital ( Site 2000)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82220723511
-
Seoul, Jižní Korea, 03722
- Nábor
- Severance Hospital, Yonsei University Health System ( Site 2002)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82222282230
-
Seoul, Jižní Korea, 05505
- Nábor
- Asan Medical Center ( Site 2003)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82230103646
-
Seoul, Jižní Korea, 06351
- Nábor
- Samsung Medical Center ( Site 2001)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 82234101382
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Jižní Korea, 10408
- Nábor
- National Cancer Center ( Site 2004)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 82319201760
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- Nábor
- Princess Margaret Cancer Centre ( Site 0101)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 416-946-2818
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3J1
- Nábor
- McGill University Health Centre ( Site 0100)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 514-934-1934x31975
-
Montreal, Quebec, Kanada, H2X 0A9
- Nábor
- Centre Hospitalier de l'Université de Montréal ( Site 0102)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 514-890-8000
-
-
-
-
-
Manchester, Spojené království, M20 4BX
- Nábor
- The Christie NHS Foundation Trust ( Site 0405)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +441619187689
-
-
East Sussex
-
Brighton, East Sussex, Spojené království, BN2 1ES
- Nábor
- University Hospitals Sussex NHS Foundation Trust ( Site 0404)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +44 01273 696 955
-
-
England
-
Fulham, England, Spojené království, SW3 6JJ
- Nábor
- Royal Marsden Hospital ( Site 0402)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +442078118084
-
Sutton, England, Spojené království, SM2 5PT
- Nábor
- The Royal Marsden NHS Foundation Trust. ( Site 0403)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +442078118084
-
-
London, City of
-
London, London, City of, Spojené království, E1 1RD
- Nábor
- Barts Health NHS Trust ( Site 0401)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 020 7377 7000
-
London, London, City of, Spojené království, SE1 3SS
- Nábor
- Guy s & St Thomas NHS Foundation Trust ( Site 0400)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +44 020 7188 7188
-
-
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06510
- Nábor
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 203-785-2404
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- Nábor
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 502-562-3429
-
-
Louisiana
-
Shreveport, Louisiana, Spojené státy, 71103
- Nábor
- TRIALS 365 ( Site 0020)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 318-408-1198
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Dana-Farber Cancer Institute ( Site 0015)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 877-338-7425
-
-
New York
-
New York, New York, Spojené státy, 10065
- Nábor
- Memorial Sloan Kettering Cancer Center ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 212-639-2000
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- Nábor
- OU Health University of Oklahoma Medical Center ( Site 7000)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 405-271-1112
-
-
Texas
-
Fort Worth, Texas, Spojené státy, 76104
- Nábor
- Texas Oncology - DFW ( Site 8000)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 615-329-7430
-
Houston, Texas, Spojené státy, 77030
- Dokončeno
- Houston Methodist Hospital ( Site 0010)
-
-
Utah
-
West Valley City, Utah, Spojené státy, 84119
- Nábor
- START Mountain Region ( Site 0008)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 801-907-4750
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- Nábor
- University of Virginia Health System ( Site 0011)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 434-924-9333
-
-
-
-
-
Taipei, Tchaj-wan, 100225
- Nábor
- National Taiwan University Hospital ( Site 3001)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +886223123456
-
Taoyuan, Tchaj-wan, 33305
- Nábor
- Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +88633281200
-
-
-
-
-
Barcelona, Španělsko, 08035
- Nábor
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +349325434528607
-
Madrid, Španělsko, 28041
- Nábor
- Hospital Universitario 12 de Octubre ( Site 0304)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34913908626
-
Madrid, Španělsko, 28040
- Nábor
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 34915504800 x2805
-
Málaga, Španělsko, 29010
- Nábor
- Hospital Universitario Virgen de la Victoria ( Site 0306)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34951032508
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Španělsko, 08908
- Nábor
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34932607744
-
-
Madrid
-
Majadhonda, Madrid, Španělsko, 28222
- Nábor
- HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34 911917358
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Španělsko, 28027
- Nábor
- Clinica Universidad de Navarra ( Site 0301)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +349135319207513
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Španělsko, 46014
- Nábor
- Hospital General Universitario de Valencia ( Site 0305)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +34 963187527
-
-
-
-
-
Sankt Gallen, Švýcarsko, 9000
- Nábor
- HOCH Health Ostschweiz ( Site 0801)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +41714941111
-
-
Canton of Basel-City
-
Basel, Canton of Basel-City, Švýcarsko, 4031
- Nábor
- University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +41613284214
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, Švýcarsko, 1011
- Nábor
- CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +41795567362
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
- Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
- Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
- Has provided tumor tissue for biomarker research (all cohorts)
- Has an Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
- Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant
Exclusion Criteria:
- Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
- Has ≥Grade 2 peripheral neuropathy
- Has received prior treatment with cadherin-6-targeted agents
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Receives chronic steroid treatment
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)
Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Experimentální: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)
Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Experimentální: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)
Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Experimentální: Cohort B-1 (R-DXd + Bevacizumab)
Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
|
|
Experimentální: Cohort B-2 (R-DXd RP2D + Bevacizumab)
Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
|
|
Experimentální: Cohort C-1 (R-DXd + Pembrolizumab)
Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Experimentální: Cohort D (R-DXd +/- Bevacizumab)
Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
|
|
Experimentální: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
|
|
Experimentální: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
|
|
Aktivní komparátor: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)
Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV injection on days 1 and 8 of each 3-week Cycle IV injection administered on Day 1 of each 4-week cycle
Ostatní jména:
|
|
Experimentální: Cohort E-1 (R-DXd + MK-2010)
Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle |
|
Experimentální: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)
Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles). |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Experimentální: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)
Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Experimentální: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)
Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease. |
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle.
Ostatní jména:
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Časové okno: Up to 21 days
|
DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Časové okno: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported. |
Up to approximately 3 years
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Časové okno: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Objective Response Rate (ORR)
Časové okno: Up to approximately 3 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Časové okno: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1: Objective Response Rate (ORR)
Časové okno: Up to approximately 3 years
|
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR). |
Up to approximately 3 years
|
|
Part 2: Duration of Response (DOR)
Časové okno: Up to approximately 3 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Časové okno: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Overall Survival (OS)
Časové okno: Up to approximately 5 years
|
OS is defined as the time from the first dose of study treatment to death due to any cause. |
Up to approximately 5 years
|
|
Part 2: Number of Participants with One or More AEs
Časové okno: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Časové okno: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Medical Director, Merck Sharp & Dohme LLC
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Koordinační komplexy
- Taxoidy
- Cyclodecanes
- Diterpeny
- Deoxycytidin
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Bevacizumab
- Gemcitabin
- Karboplatina
- Paklitaxel
- Pembrolizumab
- Liposomální doxorubicin
- 1-dodecylpyridoxal
Další identifikační čísla studie
Další identifikační čísla studie
- 5909-003
- MK-5909-003 (Jiný identifikátor: MSD)
- U1111-1308-2821 (Identifikátor registru: UTN)
- 2024-514674-47-00 (Identifikátor registru: EU CT)
- REJOICE-Ovarian02 (Jiný identifikátor: MSD)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .